Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Animals Antibodies, Neutralizing / blood CD4-Positive T-Lymphocytes / immunology HIV Antibodies / blood HIV Antigens / immunology HIV Infections / immunology HIV-1 / immunology Humans Macaca mulatta Male Vaccination Vaccinia virus / immunology Viral Vaccines / administration & dosage Virus Replication env Gene Products, Human Immunodeficiency Virus / immunology

Gag-Pol-Nef HIV NYVAC NYVAC-KC T cell response antibody responses gp140 nonhuman primates vaccines

Journal

Journal of virology

ISSN: 1098-5514

Titre abrégé: J Virol

Pays: United States

ID NLM: 0113724

Informations de publication

Date de publication:
01 02 2019

Historique:

received: 13 09 2018

accepted: 31 10 2018

pubmed: 16 11 2018

medline: 9 11 2019

entrez: 16 11 2018

Statut: epublish

Résumé

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here, we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and were used as the prime, with recombinant virus plus envelope protein used as the boost. In nearly every T and B cell immune assay against HIV-1, including neutralization and antibody binding, NYVAC-C-KC induced a greater immune response than NYVAC-C, indicating that replication competence in a poxvirus may improve upon the modestly successful regimen used in the RV144 clinical trial.

Identifiants

DOI: 10.1128/JVI.01513-18 PMID: 30429340 PMC: PMC6340019

pubmed: 30429340

pii: JVI.01513-18

doi: 10.1128/JVI.01513-18

pmc: PMC6340019

pii:

doi:

Substances chimiques

Antibodies, Neutralizing 0

HIV Antibodies 0

HIV Antigens 0

NYVAC vaccine 0

Viral Vaccines 0

env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : NIAID NIH HHS

ID : R01 AI118581

Pays : United States

Organisme : NCATS NIH HHS

ID : UL1 TR001414

Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

J Immunol Methods. 2012 Dec 14;386(1-2):10-21

pubmed: 22955212

Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24

pubmed: 23661056

J Virol. 2017 Apr 13;91(9):

pubmed: 28179536

Virology. 1992 May;188(1):217-32

pubmed: 1566575

N Engl J Med. 2012 Apr 5;366(14):1275-86

pubmed: 22475592

Virology. 2008 Mar 15;372(2):273-90

pubmed: 18061231

Vaccine. 2008 Jun 13;26(25):3162-74

pubmed: 18502003

J Immunol. 2012 May 15;188(10):5166-76

pubmed: 22529301

Vaccine. 2013 Aug 2;31(35):3502-18

pubmed: 23707164

Dev Biol Stand. 1994;82:65-9

pubmed: 7958484

J Clin Immunol. 2001 May;21(3):227-33

pubmed: 11403230

Virology. 2006 Sep 30;353(2):268-82

pubmed: 17039602

Curr Opin HIV AIDS. 2016 Nov;11(6):561-568

pubmed: 27559708

J Immunol. 2003 Dec 1;171(11):5663-7

pubmed: 14634071

Stat Biopharm Res. 2009 Feb 1;1(1):81-91

pubmed: 20072667

Sci Transl Med. 2015 Oct 21;7(310):310rv7

pubmed: 26491081

Science. 2002 Jun 28;296(5577):2354-60

pubmed: 12089434

J Virol. 2009 Jun;83(11):5881-9

pubmed: 19321612

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53

pubmed: 8876138

PLoS One. 2016 Apr 14;11(4):e0153484

pubmed: 27077384

J Virol. 2008 Dec;82(24):12449-63

pubmed: 18842730

Annu Rev Med. 2015;66:423-37

pubmed: 25341006

J Gen Virol. 2015 Jun;96(Pt 6):1478-1483

pubmed: 25667320

J Immunol. 2005 Feb 15;174(4):2185-9

pubmed: 15699150

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S75-88

pubmed: 15285707

J Virol. 2016 Mar 28;90(8):4133-4149

pubmed: 26865719

Nat Med. 2016 Jul;22(7):762-70

pubmed: 27239761

Syst Synth Biol. 2010 Sep;4(3):215-25

pubmed: 21189842

Cytometry A. 2011 Aug;79(8):603-12

pubmed: 21735545

Vaccines (Basel). 2014 Mar;2(1):15-35

pubmed: 24932411

J Virol. 2015 Aug;89(16):8525-39

pubmed: 26041302

PLoS Comput Biol. 2015 Feb 03;11(2):e1003973

pubmed: 25646817

N Engl J Med. 2009 Dec 3;361(23):2209-20

pubmed: 19843557

J Virol. 2013 Feb;87(3):1708-19

pubmed: 23175374

J Exp Med. 2008 Jan 21;205(1):63-77

pubmed: 18195071

PLoS Pathog. 2018 Feb 23;14(2):e1006888

pubmed: 29474461

J Virol. 2014 Aug;88(15):8242-55

pubmed: 24829343

AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1197-205

pubmed: 12487826

J Virol. 2015 Jan 15;89(2):970-88

pubmed: 25355891

Curr Opin HIV AIDS. 2016 Nov;11(6):585-592

pubmed: 27607594

Curr Opin HIV AIDS. 2013 Sep;8(5):402-11

pubmed: 23925000

AIDS. 2011 Nov 13;25(17):2089-97

pubmed: 21832938

Vaccine. 2008 Jun 13;26(25):3153-61

pubmed: 18502002

PLoS One. 2011;6(11):e25674

pubmed: 22096477

Vaccine. 2011 Aug 26;29(37):6191-218

pubmed: 21718747

Vaccine. 2011 Dec 9;30(1):78-94

pubmed: 22037204

J Virol. 2019 Jan 17;93(3):

pubmed: 30429343

PLoS Pathog. 2015 Aug 12;11(8):e1005101

pubmed: 26267144

J Virol. 2015 Jun;89(12):6462-80

pubmed: 25855741

Expert Rev Vaccines. 2013 Dec;12(12):1395-416

pubmed: 24168097

J Infect Dis. 2004 Dec 1;190(11):1970-8

pubmed: 15529262

PLoS One. 2016 Jul 21;11(7):e0157391

pubmed: 27442017